Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies

Regulatory information
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, today announced that on its Capital Markets Days in Stockholm, the company presented an update on the number of patients included in the company’s clinical studies.

Hansa Medical’s Capital Market Day in Stockholm attracted an audience of some 70 people at IVA Konferenscetrum in Stockholm and was followed live via webcast by an additional 270 viewers. Senior management from Hansa Medical, including Göran Arvidson, Dr Christian Kjellman, Dr Lena Winstedt, Dr Sam Agus, Henk Doude van Troostwijk and Emanuel Björne presented in-depth talks on the company, the market and their proprietary products.

Data from studies with lead product IdeS published in The New England Journal of Medicine (August 3, 2017) was presented by co-lead authors Dr Stanley Jordan from Cedars-Sinai Medical Center, Los Angeles, and Dr Tomas Lorant from Uppsala University Hospital, Sweden.

The presentations offered a broader and deeper picture of the company, its prioritized indications and its future opportunities. Hansa Medical issued a press release at 8.30 am on the same day (October 3, 2017) to inform on three news items that would be covered in the presentations.

The status of the ongoing clinical Phase II studies with the lead drug candidate IdeS in kidney transplantation, where the number of patients treated with IdeS prior to kidney transplantation now amounts to 42.

The status of the ongoing investigator initiated Phase II study in severe anti-GBM antibody disease, where in total now two patients have been included in the study. Prior to site initiation of the ongoing study, three patients were treated on named patient basis in Sweden. The patients have all responded favorably and IdeS appears to be well tolerated in these patients so far.

An update was also given on the company’s cash position as of September 30, amounting to SEK 131 million in cash and cash equivalents, as compared to SEK 170 million at the end of second quarter 2017.

Follow up data on the first patient transplanted after desensitization with IdeS was presented demonstrating continuous normalized creatinine levels three years post kidney transplantation.

This information is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 7:15 PM CEST on October 3 2017.